Review
. 2010 Oct;7(12).
doi: 10.1038/nrclinonc.2010.170.

Breast cancer assessment tools and optimizing adjuvant therapy

Catherine Oakman 1 Libero Santarpia  Angelo Di Leo  
Affiliations
  • PMID: 20975745
  •     60 References
  •     38 citations

Abstract

Recommendation of systemic adjuvant therapy and choice of optimal agents for early-stage breast cancer remains a challenge. Adjuvant therapy is indicated on the assumption of residual micrometastatic disease. Adjuvant assessment tools for prognosis and prediction of treatment benefit, including Adjuvant! Online, the St Gallen Consensus, Oncotype DX(®) and MammaPrint(®), aid clinical decision making. However, all of these tools have limitations that must be considered in their judicious application. Clinicopathological based tools are critically dependent on accurate, standardized measurement of parameters. Multigene tools are appealing for their objectivity and reproducibility, particularly regarding analysis of proliferation, but these approaches still overlook the biological heterogeneity within tumors evidenced by distinct cell subpopulations with different genomic patterns and function. The greatest treatment challenge remains for patients assessed as intermediate risk of relapse, a problem not overcome by multigene tools. Remarkable diversity in breast cancer dictates that adjuvant management must be biologically driven. Future identification of predictive biomarkers for specific chemotherapy sensitivity may allow targeted use of available agents, including anthracyclines, taxanes and DNA damaging agents. The presence of drug targets and targetable signaling pathways, rather than molecularly defined subgroups, may ultimately drive treatment decisions.

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
C Liedtke, K Broglio, +11 authors, A M Gonzalez-Angulo.
Ann Oncol, 2009 Jul 15; 20(12). PMID: 19596702    Free PMC article.
Highly Cited.
HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
Pia Wülfing, Julia Borchard, +4 authors, Burkhard Brandt.
Clin Cancer Res, 2006 Mar 23; 12(6). PMID: 16551854
Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes.
Jeffrey S Ross, W Fraser Symmans, Lajos Pusztai, Gabriel N Hortobagyi.
Clin Cancer Res, 2007 May 17; 13(10). PMID: 17504980
Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers.
Chiyomi Egawa, Kazuyoshi Motomura, +6 authors, Shinzaburo Noguchi.
Breast Cancer Res Treat, 2003 Mar 04; 78(1). PMID: 12611456
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.
A Rhodes, B Jasani, A J Balaton, K D Miller.
J Clin Pathol, 2000 May 24; 53(4). PMID: 10823126    Free PMC article.
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
M F Press, L Bernstein, +12 authors, K J Flom.
J Clin Oncol, 1997 Aug 01; 15(8). PMID: 9256133
Highly Cited.
Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
Wedad Hanna, Sharon Nofech-Mozes, Harriette J Kahn.
Breast J, 2007 Feb 27; 13(2). PMID: 17319852
A simple system for grading the response of breast cancer to neoadjuvant chemotherapy.
S Rodenhuis, I A M Mandjes, +4 authors, S C Linn.
Ann Oncol, 2009 Sep 01; 21(3). PMID: 19717533
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Marieke E Straver, Annuska M Glas, +7 authors, Sjoerd Rodenhuis.
Breast Cancer Res Treat, 2009 Feb 14; 119(3). PMID: 19214742
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
The humoral immune system has a key prognostic impact in node-negative breast cancer.
Marcus Schmidt, Daniel Böhm, +7 authors, Mathias Gehrmann.
Cancer Res, 2008 Jul 03; 68(13). PMID: 18593943
Highly Cited.
Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer.
N Xenidis, V Markos, +10 authors, V Georgoulias.
Ann Oncol, 2007 May 23; 18(10). PMID: 17515404
The Nottingham Prognostic Index in primary breast cancer.
M H Galea, R W Blamey, C E Elston, I O Ellis.
Breast Cancer Res Treat, 1992 Jan 01; 22(3). PMID: 1391987
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, +7 authors, Charles M Perou.
Clin Cancer Res, 2007 Apr 18; 13(8). PMID: 17438091
Highly Cited.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Jolien M Bueno-de-Mesquita, Wim H van Harten, +19 authors, Sabine C Linn.
Lancet Oncol, 2007 Nov 29; 8(12). PMID: 18042430
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.
Andrew E Teschendorff, Ahmad Miremadi, +2 authors, Carlos Caldas.
Genome Biol, 2007 Aug 09; 8(8). PMID: 17683518    Free PMC article.
Highly Cited.
Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes.
E N Stathopoulos, E Sanidas, +6 authors, V Georgoulias.
Ann Oncol, 2005 Jan 26; 16(2). PMID: 15668277
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients.
R Stuart-Harris, C Caldas, S E Pinder, P Pharoah.
Breast, 2008 May 06; 17(4). PMID: 18455396
Highly Cited. Systematic Review.
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.
Jean-Yves Pierga, François-Clément Bidard, +7 authors, Michel Marty.
Clin Cancer Res, 2008 Nov 05; 14(21). PMID: 18980996
Highly Cited.
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems.
A Rhodes, B Jasani, +2 authors, K D Miller.
J Clin Pathol, 2000 Apr 18; 53(2). PMID: 10767828    Free PMC article.
A pooled analysis of bone marrow micrometastasis in breast cancer.
Stephan Braun, Florian D Vogl, +19 authors, Klaus Pantel.
N Engl J Med, 2005 Aug 27; 353(8). PMID: 16120859
Highly Cited.
Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial.
Michael Mengel, Reinhard von Wasielewski, +3 authors, Hans Kreipe.
J Pathol, 2002 Oct 11; 198(3). PMID: 12375261
Pathological definition of triple negative breast cancer.
Giuseppe Viale, Luca Bottiglieri.
Eur J Cancer, 2009 Sep 25; 45 Suppl 1. PMID: 19775600
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.
Pierre Farmer, Hervé Bonnefoi, +18 authors, Mauro Delorenzi.
Nat Med, 2009 Jan 06; 15(1). PMID: 19122658
Highly Cited.
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
Stella Mook, Marjanka K Schmidt, +6 authors, Peter M Ravdin.
Lancet Oncol, 2009 Oct 06; 10(11). PMID: 19801202
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study.
Gianni Bonadonna, Angela Moliterni, +4 authors, Pinuccia Valagussa.
BMJ, 2005 Jan 15; 330(7485). PMID: 15649903    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W Jeffrey Allard, Jeri Matera, +6 authors, Leon W M M Terstappen.
Clin Cancer Res, 2004 Oct 27; 10(20). PMID: 15501967
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
Michail Ignatiadis, Galatea Kallergi, +8 authors, Dimitris Mavroudis.
Clin Cancer Res, 2008 May 03; 14(9). PMID: 18451221
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Stephen Chia, Brian Norris, +7 authors, Karen Gelmon.
J Clin Oncol, 2008 Nov 13; 26(35). PMID: 19001334
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.
C L Carter, C Allen, D E Henson.
Cancer, 1989 Jan 01; 63(1). PMID: 2910416
Highly Cited.
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
Giuseppe Curigliano, Giuseppe Viale, +10 authors, Aron Goldhirsch.
J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884553
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Carsten Denkert, Sibylle Loibl, +14 authors, Gunter von Minckwitz.
J Clin Oncol, 2009 Nov 18; 28(1). PMID: 19917869
Highly Cited.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.
Michael Knauer, Stella Mook, +7 authors, Laura J van 't Veer.
Breast Cancer Res Treat, 2010 Mar 06; 120(3). PMID: 20204499
Is there a role for circulating tumor cells in the management of breast cancer?
Daniel F Hayes, Jeffrey Smerage.
Clin Cancer Res, 2008 Jun 19; 14(12). PMID: 18559576
Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.
Katharina Pachmann, Oumar Camara, +11 authors, Klaus Höffken.
J Clin Oncol, 2008 Mar 08; 26(8). PMID: 18323545
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
C Simmons, N Miller, +4 authors, M J Clemons.
Ann Oncol, 2009 Mar 21; 20(9). PMID: 19299408    Free PMC article.
Highly Cited.
Inferring tumor progression from genomic heterogeneity.
Nicholas Navin, Alexander Krasnitz, +13 authors, Michael Wigler.
Genome Res, 2009 Nov 12; 20(1). PMID: 19903760    Free PMC article.
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory.
Merdol Ibrahim, Andrew Dodson, +3 authors, Keith Miller.
Am J Clin Pathol, 2008 Feb 21; 129(3). PMID: 18285262
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
Lajos Pusztai, Jong-Hyeon Jeong, +8 authors, W Fraser Symmans.
J Clin Oncol, 2009 Aug 12; 27(26). PMID: 19667268    Free PMC article.
Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.
Nikos Xenidis, Maria Perraki, +13 authors, Dimitris Mavroudis.
J Clin Oncol, 2006 Jun 14; 24(23). PMID: 16769987
Proliferation marker Ki-67 in early breast cancer.
Ander Urruticoechea, Ian E Smith, Mitch Dowsett.
J Clin Oncol, 2005 Sep 30; 23(28). PMID: 16192605
Highly Cited. Review.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Christine Desmedt, Benjamin Haibe-Kains, +6 authors, Christos Sotiriou.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698033
Highly Cited.
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.
Glenn D Francis, Margaret Dimech, Leanne Giles, Alison Hopkins.
J Clin Pathol, 2007 Jan 30; 60(11). PMID: 17259294    Free PMC article.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
J Clin Oncol, 2010 Apr 21; 28(16). PMID: 20404251    Free PMC article.
Highly Cited. Systematic Review.
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
A Goldhirsch, W C Wood, +4 authors, 10th St. Gallen conference.
Ann Oncol, 2007 Aug 07; 18(7). PMID: 17675394
Highly Cited. Review.
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
Philippe L Bedard, Fatima Cardoso.
Nat Rev Clin Oncol, 2011 Mar 03; 8(5). PMID: 21364525
Review.
Future medical applications of single-cell sequencing in cancer.
Nicholas Navin, James Hicks.
Genome Med, 2011 Jun 03; 3(5). PMID: 21631906    Free PMC article.
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer.
Armando E Giuliano, Debra Hawes, +9 authors, Richard Cote.
JAMA, 2011 Jul 28; 306(4). PMID: 21791687    Free PMC article.
Challenges translating breast cancer gene signatures into the clinic.
Britta Weigelt, Lajos Pusztai, Alan Ashworth, Jorge S Reis-Filho.
Nat Rev Clin Oncol, 2011 Sep 01; 9(1). PMID: 21878891
Review.
The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities.
Eun-Kyoung Yim Breuer, Mandi M Murph.
Int J Proteomics, 2011 Sep 03; 2011. PMID: 21886869    Free PMC article.
Insight into the heterogeneity of breast cancer through next-generation sequencing.
Hege G Russnes, Nicholas Navin, James Hicks, Anne-Lise Borresen-Dale.
J Clin Invest, 2011 Oct 04; 121(10). PMID: 21965338    Free PMC article.
Highly Cited. Review.
External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.
David Hajage, Yann de Rycke, +11 authors, Fabien Reyal.
PLoS One, 2011 Nov 17; 6(11). PMID: 22087319    Free PMC article.
Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer.
Stephan Gade, Christine Porzelius, +6 authors, Tim Beissbarth.
BMC Bioinformatics, 2011 Dec 23; 12. PMID: 22188670    Free PMC article.
Apoptosis - associated genes and their role in predicting responses to neoadjuvant breast cancer treatment.
Daniel Tvrdík, Helena Skálová, +5 authors, Luboš Petruželka.
Med Sci Monit, 2011 Dec 31; 18(1). PMID: 22207111    Free PMC article.
Translating cancer 'omics' to improved outcomes.
Emily A Vucic, Kelsie L Thu, +4 authors, Wan L Lam.
Genome Res, 2012 Feb 04; 22(2). PMID: 22301133    Free PMC article.
Transcriptomic landscape of breast cancers through mRNA sequencing.
Jeyanthy Eswaran, Dinesh Cyanam, +7 authors, Rakesh Kumar.
Sci Rep, 2012 Feb 23; 2. PMID: 22355776    Free PMC article.
Beyond PSA: the next generation of prostate cancer biomarkers.
John R Prensner, Mark A Rubin, John T Wei, Arul M Chinnaiyan.
Sci Transl Med, 2012 Mar 31; 4(127). PMID: 22461644    Free PMC article.
Highly Cited. Review.
JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21.
Xinyi Yang, Wei Wang, +5 authors, Ruiwen Zhang.
PLoS One, 2012 May 05; 7(4). PMID: 22558087    Free PMC article.
Are there biologic differences between male and female breast cancer explaining inferior outcome of men despite equal stage and treatment?!
A-C Müller, C Gani, +4 authors, M Weinmann.
Strahlenther Onkol, 2012 Aug 01; 188(9). PMID: 22847517
Epigenetics advancing personalized nanomedicine in cancer therapy.
Shujun Liu.
Adv Drug Deliv Rev, 2012 Aug 28; 64(13). PMID: 22921595    Free PMC article.
Review.
Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues.
Maurizio Callari, Matteo Dugo, +7 authors, Loris De Cecco.
PLoS One, 2012 Oct 03; 7(9). PMID: 23028787    Free PMC article.
Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.
Russell M Medford, T Forcht Dagi, Robert S Rosenson, Margaret K Offermann.
Curr Atheroscler Rep, 2013 Mar 21; 15(5). PMID: 23512605
Review.
Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.
Grigorijs Plakhins, Arvids Irmejs, +7 authors, Janis Gardovskis.
Fam Cancer, 2013 May 04; 12(4). PMID: 23640109
The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions.
Berit Maria Müller, Elke Keil, +16 authors, Carsten Denkert.
PLoS One, 2013 Jul 05; 8(6). PMID: 23826382    Free PMC article.
The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: a 10-year follow-up study.
Mei-Chi Hsu, Kuo-Ting Lee, +4 authors, Kung-Chia Young.
BMC Cancer, 2013 Jul 09; 13. PMID: 23829168    Free PMC article.
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Josh J Carlson, Joshua A Roth.
Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828    Free PMC article.
Highly Cited. Systematic Review.
Bench-to-bedside review: future novel diagnostics for sepsis - a systems biology approach.
Simon Skibsted, Manoj K Bhasin, William C Aird, Nathan I Shapiro.
Crit Care, 2013 Oct 08; 17(5). PMID: 24093155    Free PMC article.
Review.
The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.
Wei Wang, Jiang-Jiang Qin, +8 authors, Ruiwen Zhang.
Nat Commun, 2014 Oct 02; 5. PMID: 25271708    Free PMC article.
Breast cancer therapy planning - a novel support concept for a sequential decision making problem.
Alexander Scherrer, Ilka Schwidde, +3 authors, Karl-Heinz Küfer.
Health Care Manag Sci, 2014 Oct 16; 18(3). PMID: 25315184
Clinicians' expectations for gene-driven cancer therapy.
Antti Jekunen.
Clin Med Insights Oncol, 2015 Jan 13; 8. PMID: 25574148    Free PMC article.
Review.
Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models.
E Laas, P Mallon, +7 authors, F Reyal.
Br J Cancer, 2015 Jan 16; 112(5). PMID: 25590666    Free PMC article.
Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice.
Linxiang Lan, Jane D Holland, +6 authors, Walter Birchmeier.
EMBO J, 2015 Mar 05; 34(11). PMID: 25736378    Free PMC article.
Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma.
Do Joong Park, An Na Seo, +8 authors, Sam S Yoon.
Ann Surg Oncol, 2015 Aug 12; 22 Suppl 3. PMID: 26259755    Free PMC article.
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.
Antonio Martínez-Aranda, Vanessa Hernández, +16 authors, Angels Sierra.
Oncotarget, 2015 Oct 27; 6(42). PMID: 26497551    Free PMC article.
The Performance of the Nottingham Prognosis Index and the Adjuvant Online Decision Making Tool for Prognosis in Early-stage Breast Cancer Patients.
Mehri Rejali, Mehdi Tazhibi, +2 authors, Reyhane Mokarian.
Int J Prev Med, 2015 Nov 26; 6. PMID: 26605014    Free PMC article.
SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer.
Lauren L Siewertsz van Reesema, Vasilena Zheleva, +17 authors, Amy H Tang.
EBioMedicine, 2016 Aug 30; 11. PMID: 27569656    Free PMC article.
The recurrent architecture of tumour initiation, progression and drug sensitivity.
Andrea Califano, Mariano J Alvarez.
Nat Rev Cancer, 2016 Dec 16; 17(2). PMID: 27977008    Free PMC article.
Highly Cited. Review.
Personalized chemotherapy selection for breast cancer using gene expression profiles.
Kaixian Yu, Qing-Xiang Amy Sang, +6 authors, Jinfeng Zhang.
Sci Rep, 2017 Mar 04; 7. PMID: 28256629    Free PMC article.
RAS pathway biomarkers for breast cancer prognosis.
Lauren L Siewertsz van Reesema, Michael P Lee, +5 authors, Amy H Tang.
Clin Lab Int, 2017 Jun 06; 40. PMID: 28579913    Free PMC article.
Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells.
Azam Akbari, Azim Akbarzadeh, +3 authors, Mohammad Reza Mehrabi.
Adv Pharm Bull, 2020 Feb 01; 10(1). PMID: 32002360    Free PMC article.
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
T A Chan, M Yarchoan, +4 authors, S Peters.
Ann Oncol, 2018 Nov 06; 30(1). PMID: 30395155    Free PMC article.
Highly Cited. Review.
Rapid Microwave-Assisted Cisplatin-Loaded Solid Lipid Nanoparticles: Synthesis, Characterization and Anticancer Study.
Hibah M Aldawsari, Sima Singh.
Nanomaterials (Basel), 2020 Mar 15; 10(3). PMID: 32168934    Free PMC article.
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Abiola Ibraheem, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2020 Jun 11; 126(17). PMID: 32521056    Free PMC article.